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Background: The antianginal efficacy through heart rate reduction by ivabradine has been studied in controlled trials. The objective of the 
REDUCTION multicenter study was to evaluate the efficacy and safety of ivabradine in every day clinical practice. We performed a subgroup analysis 
to evaluate the efficacy of ivabradine in patients with stable angina pectoris who already underwent PCI.
Methods: 1712 patients were followed for 4 months. Patients were treated with ivabradine at doses of 2.5, 5 or 7.5 mg bid for 4 months. After 
baseline evaluation two visits were conducted after 1 and 4 months. Heart rate (HR) at rest, the number of angina attacks, nitrate consumption, 
overall efficacy and tolerance according to the physicians’ judgement were evaluated. Baseline and last observation values were compared.
Results: All 1712 patients had undergone PCI. 43% of patients had a history of myocardial infarction. Almost all patients received concomitant 
standard medication (e.g. ACEI 60%, long acting nitrates 21%). 
Baseline
With ivabradine
after 4 months
p-value
Heart Rate
(bpm)
80.8 ± 14.4 69.4 ± 8.5 < 0.0001
Angina attacks
(per week)
2.2 ± 2.9 0.4 ± 2.0 < 0.0001
Nitrate consumption
(per week)
3.0 ± 3.8 0.4 ± 1.2 < 0.0001
Ivabradine reduced mean HR by 11.5 bpm in a mean dose of 10.8 mg per day. 77% of the patients had at least one angina attack per week. The 
number of angina attacks and nitrate consumption was significantly reduced (s. Table).
Conclusions: Ivabradine reduced heart rate, angina pectoris and nitrate consumption in patients with coronary artery disease post PCI. Thus, 
ivabradine provides additional clinical benefit in the complex patient group which suffers from ongoing angina symptoms despite successful PCI.
